CN111973554A - Eye-protecting liquid - Google Patents
Eye-protecting liquid Download PDFInfo
- Publication number
- CN111973554A CN111973554A CN202010917740.7A CN202010917740A CN111973554A CN 111973554 A CN111973554 A CN 111973554A CN 202010917740 A CN202010917740 A CN 202010917740A CN 111973554 A CN111973554 A CN 111973554A
- Authority
- CN
- China
- Prior art keywords
- eye
- component
- percentage
- raw materials
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 238000003756 stirring Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 229960003237 betaine Drugs 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 239000004744 fabric Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims 5
- 208000003464 asthenopia Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 239000003889 eye drop Substances 0.000 abstract description 4
- 230000004438 eyesight Effects 0.000 abstract description 4
- 206010013774 Dry eye Diseases 0.000 abstract description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 210000001328 optic nerve Anatomy 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000001741 anti-phlogistic effect Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an eye-protecting liquid which comprises A, B, C three components, and the eye-protecting liquid has the advantages of reasonable raw material matching, good environmental protection, mildness and no stimulation, and has the effects of nourishing optic nerves, relieving eye fatigue, eliminating dry eyes and improving eyesight. The eye drop has good applicability, does not generate any side effect even if being used for a long time, and has high safety.
Description
Technical Field
The invention belongs to the field of medical care, and particularly relates to eye-protecting liquid.
Background
Along with the development of high technology, the lives of people are more diversified, but the eyes are used more frequently, in life, work, study and even leisure time, electronic products are in the lives of people all the time, so that the burden of the eyes is increased, modern people have frequent eye diseases and various causes, but the most direct factor for the frequent eye diseases is faced with computers and mobile phones for a long time, students who are on a long-term basis, people with white collars and excessive eyes are busy in work, mobile phones are played and computers are more frequently, some overloaded display screens cannot be left dark, the normal biological clock of the human body is disturbed, and the bad life habits bring the symptoms of pain around eyes and eye sockets, blurred vision, dry eyes, lacrimation, severe headache, and the like to people over time, so that the symptoms are called as asthenopia vertigo syndrome;
there are many eye drops on the market for eye diseases, which have different symptoms but mainly comprise several components: although the dosage of the antiseptic, the hormone, the antibiotic and the antiphlogistic ingredients is small, and the antiseptic, the hormone, the antibiotic and the antiphlogistic ingredients do not cause damage to eyes when being used in a small amount, but the long-term use of the antiseptic, the hormone, the antibiotic and the antiphlogistic ingredients can not relieve eye fatigue and improve eye diseases but can damage the eyes and aggravate the eye diseases.
Disclosure of Invention
The invention aims to provide eye protecting water.
In order to achieve the purpose, the invention adopts the following technical scheme:
an eye-protecting liquid comprises A, B, C three components.
The component A comprises the following raw materials in percentage by weight:
260-10% of glycerol polyether, 0-2% of p-hydroxyacetophenone, 0-30% of propylene glycol, 0-10% of betaine, 0-5% of sodium hyaluronate and the balance of water.
The component B comprises the following raw materials in percentage by weight:
menthol 0-20%, the rest is PEG-40 hydrogenated castor oil.
The component C comprises the following raw materials in percentage by weight:
pyridoxine 0-40%, taurine 0-16%, and 1, 2-hexanediol in balance.
The preparation method of the eye-protecting water comprises the following steps:
(1) adding the component A into an emulsifying pot, uniformly stirring, heating to 80-85 ℃, preserving heat and stirring for 30-40 minutes;
(2) cooling to 40-45 deg.C, sequentially adding B, C components, and stirring;
(3) and (5) inspecting, and filtering and discharging the qualified product by using 500-mesh filter cloth.
The invention has the advantages that:
the eye drop has the beneficial effects that the eye drop is reasonable in raw material matching, good in environmental friendliness, mild and non-irritant, has the effects of nourishing optic nerves, relieving eye fatigue, eliminating eye dryness and improving eyesight, is good in applicability, does not produce any side effect even after being used for a long time, and is high in safety.
Detailed Description
Example 1
An eye-protecting liquid comprises A, B, C three components.
The component A comprises the following raw materials in percentage by weight:
glycerin polyether-261%, p-hydroxyacetophenone 1%, betaine 1%, sodium hyaluronate 1%, and the balance of water.
The component B comprises the following raw materials in percentage by weight:
menthol 5%, the remainder being PEG-40 hydrogenated castor oil.
The component C comprises the following raw materials in percentage by weight:
pyridoxine 20%, taurine 10%, and 1, 2-hexanediol as the rest.
The preparation method of the eye-protecting water comprises the following steps:
(1) adding the component A into an emulsifying pot, uniformly stirring, heating to 82 ℃, and keeping the temperature and stirring for 34 minutes;
(2) cooling to 42 deg.C, sequentially adding B, C components, and stirring;
(3) and (5) inspecting, and filtering and discharging the qualified product by using 500-mesh filter cloth.
Example 2
An eye-protecting liquid comprises A, B, C three components.
The component A comprises the following raw materials in percentage by weight:
-263% of glyceryl polyether, 10% of propylene glycol, 8% of betaine, 2% of sodium hyaluronate and the balance of water.
The component B comprises the following raw materials in percentage by weight:
menthol 10%, the remainder being PEG-40 hydrogenated castor oil.
The component C comprises the following raw materials in percentage by weight:
pyridoxine 20%, taurine 10%, and 1, 2-hexanediol as the rest.
The preparation method of the eye-protecting water comprises the following steps:
(1) adding the component A into an emulsifying pot, uniformly stirring, heating to 85 ℃, and keeping the temperature and stirring for 40 minutes;
(2) cooling to 40 ℃, sequentially adding B, C components, and uniformly stirring;
(3) and (5) inspecting, and filtering and discharging the qualified product by using 500-mesh filter cloth.
Example 3
An eye-protecting liquid comprises A, B, C three components.
The component A comprises the following raw materials in percentage by weight:
glyceryl polyether-2610%, p-hydroxyacetophenone 2%, propylene glycol 30%, betaine 10%, sodium hyaluronate 5%, and the balance of water.
The component B comprises the following raw materials in percentage by weight:
menthol 20%, the remainder being PEG-40 hydrogenated castor oil.
The component C comprises the following raw materials in percentage by weight:
pyridoxine 40%, taurine 16%, and 1, 2-hexanediol as the rest.
The preparation method of the eye-protecting water comprises the following steps:
(1) adding the component A into an emulsifying pot, uniformly stirring, heating to 85 ℃, and keeping the temperature and stirring for 30-40 minutes;
(2) cooling to 45 ℃, sequentially adding B, C components, and uniformly stirring;
(3) and (5) inspecting, and filtering and discharging the qualified product by using 500-mesh filter cloth.
And (3) performance testing:
eye fatigue relief test
160 volunteers were selected and randomly divided into four groups of 40 persons each for eye fatigue relief observation experiments. The eye protection water prepared in the first embodiment, the second embodiment and the third embodiment and the commercially available eye protection water (glittering eye protection liquid) are respectively used for the volunteers to continuously learn before the computer and have symptoms such as eye fatigue and dryness after working for 5 hours.
The experimental results are as follows:
| item | Dry and astringent condition | Has no irritation |
| Example A product | Mitigation | Is free of |
| EXAMPLE two products | Mitigation | Is free of |
| EXAMPLE three products | Mitigation | Is free of |
| Eye cream on the market | Mitigation | Slight discomfort |
And (3) vision testing:
people with age of 18-30 years are selected, myopia is detected in nearly 3 months, the vision range is 4.4-4.5, 80 people are selected and randomly grouped, 20 people in each group are respectively applied with the eye protecting water prepared in the first embodiment, the second embodiment and the third embodiment of the invention and the commercially available eye protecting water (flashing eye protecting liquid), the eyes are used once in the morning and evening, and the test period is 3 months.
The experimental results are as follows:
Claims (5)
1. an eye-protecting lotion is characterized by comprising A, B, C components.
2. The eye-protecting lotion according to claim 1, wherein the component A comprises the following raw materials in percentage by weight:
260-10% of glycerol polyether, 0-2% of p-hydroxyacetophenone, 0-30% of propylene glycol, 0-10% of betaine, 0-5% of sodium hyaluronate and the balance of water.
3. The eye-protecting lotion according to claim 1, wherein the component B comprises the following raw materials in percentage by weight:
menthol 0-20%, the rest is PEG-40 hydrogenated castor oil.
4. The eye-protecting lotion according to claim 1, wherein the component C comprises the following raw materials in percentage by weight:
pyridoxine 0-40%, taurine 0-16%, and 1, 2-hexanediol in balance.
5. The eye-protecting lotion according to any one of claims 1-4, wherein the preparation method comprises the following steps:
(1) adding the component A into an emulsifying pot, uniformly stirring, heating to 80-85 ℃, preserving heat and stirring for 30-40 minutes;
(2) cooling to 40-45 deg.C, sequentially adding B, C components, and stirring;
(3) and (5) inspecting, and filtering and discharging the qualified product by using 500-mesh filter cloth.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010917740.7A CN111973554A (en) | 2020-09-03 | 2020-09-03 | Eye-protecting liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010917740.7A CN111973554A (en) | 2020-09-03 | 2020-09-03 | Eye-protecting liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111973554A true CN111973554A (en) | 2020-11-24 |
Family
ID=73448705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010917740.7A Pending CN111973554A (en) | 2020-09-03 | 2020-09-03 | Eye-protecting liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973554A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107582605A (en) * | 2016-07-07 | 2018-01-16 | 萨尔瓦特实验室股份有限公司 | Ophthalmic composition |
| CN107913246A (en) * | 2016-10-09 | 2018-04-17 | 刘力 | The medical composite for eye of local administration |
| CN109381467A (en) * | 2018-10-24 | 2019-02-26 | 华南理工大学 | A kind of eyes flushing liquor and preparation method thereof for improving mobile phone visual fatigue and alleviating xerophthalmia |
| CN109646518A (en) * | 2019-02-20 | 2019-04-19 | 张家界茶坤缘杜仲生物科技开发有限公司 | Cortex Eucommiae eye sticker and preparation method thereof |
| CN109718245A (en) * | 2019-03-20 | 2019-05-07 | 嘉兴力山明朗生物医药科技有限公司 | A kind of collyrium and preparation method thereof for asthenopia of releiving |
| CN109843288A (en) * | 2016-10-21 | 2019-06-04 | 狮王株式会社 | Ophthalmic preparations and ophthalmic remedy |
| CN111202746A (en) * | 2020-02-27 | 2020-05-29 | 潍坊医学院附属医院 | Compound preparation for eyes and preparation method thereof |
-
2020
- 2020-09-03 CN CN202010917740.7A patent/CN111973554A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107582605A (en) * | 2016-07-07 | 2018-01-16 | 萨尔瓦特实验室股份有限公司 | Ophthalmic composition |
| CN107913246A (en) * | 2016-10-09 | 2018-04-17 | 刘力 | The medical composite for eye of local administration |
| CN109843288A (en) * | 2016-10-21 | 2019-06-04 | 狮王株式会社 | Ophthalmic preparations and ophthalmic remedy |
| CN109381467A (en) * | 2018-10-24 | 2019-02-26 | 华南理工大学 | A kind of eyes flushing liquor and preparation method thereof for improving mobile phone visual fatigue and alleviating xerophthalmia |
| CN109646518A (en) * | 2019-02-20 | 2019-04-19 | 张家界茶坤缘杜仲生物科技开发有限公司 | Cortex Eucommiae eye sticker and preparation method thereof |
| CN109718245A (en) * | 2019-03-20 | 2019-05-07 | 嘉兴力山明朗生物医药科技有限公司 | A kind of collyrium and preparation method thereof for asthenopia of releiving |
| CN111202746A (en) * | 2020-02-27 | 2020-05-29 | 潍坊医学院附属医院 | Compound preparation for eyes and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 马振友: "《中西皮肤外用制剂手册》", 30 September 2019, 河南科学技术出版社, pages: 409 - 413 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105687055B (en) | A kind of eye maintenance Essence and preparation method thereof | |
| Messaoud et al. | Improvement in ocular symptoms and signs in patients with Demodex anterior blepharitis using a novel terpinen-4-ol (2.5%) and hyaluronic acid (0.2%) cleansing wipe | |
| CN110236988B (en) | Anti-allergy and soothing multiple-restoration composition, ointment thereof and preparation method | |
| CN110840764B (en) | Cosmetic composition with long-acting skin-soothing and repairing effects and application thereof | |
| CN107375032B (en) | Composition for repairing skin barrier and preparation method thereof | |
| CN105434405A (en) | Eye-protection mask, and preparation method thereof | |
| CN111920746B (en) | Moisturizing and repairing mask and preparation method thereof | |
| CN107174560B (en) | Mild moisturizing and relieving cleansing water and preparation method thereof | |
| CN110859762B (en) | Gel containing Camellia japonica extract and having after-sun repair effect and preparation method thereof | |
| CN108653129B (en) | Skin dressing containing natural plant anti-allergy composition | |
| CN111821211A (en) | Composition with relieving and repairing effects and application thereof | |
| KR102220534B1 (en) | Soothing cream and manufacturing method for the same | |
| CN111973509A (en) | Skin care composition containing plant extract for soothing allergy | |
| CN108295022B (en) | Acne-removing composition and preparation method thereof | |
| CN112263528A (en) | Collagen jelly mask and preparation and use methods thereof | |
| CN111973554A (en) | Eye-protecting liquid | |
| CN115350130A (en) | Cosmetic composition with instant relieving effect, cosmetic and preparation method thereof | |
| CN108815083A (en) | A kind of nourishing moisturizing mildy wash and preparation method thereof | |
| CN111096914A (en) | Hemp leaf mask for cleaning and balancing face and preparation method thereof | |
| CN113925828A (en) | Borneol eye lotion | |
| CN113876671A (en) | Anti-aging composition containing rape bud extract and preparation method thereof | |
| CN109106643B (en) | Skin care composition with acne removing and anti-aging effects and preparation method of mask | |
| CN113069373A (en) | Dry eye cream, preparation method and application | |
| CN116211984B (en) | A Chinese medicinal composition eye ointment for preventing and treating myopia of children and teenagers, and its preparation method | |
| CN113425642B (en) | Eye care composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 102, building 30, Yinhu Science Park, 15 Fuxian Road, Yinhu street, Fuyang District, Hangzhou City, Zhejiang Province 310000 Applicant after: Zhejiang muzhongming Biotechnology Co.,Ltd. Address before: 310000 room 3701-4, building 2, Wangjing business center, ningwei street, Xiaoshan District, Hangzhou City, Zhejiang Province Applicant before: Zhejiang muzhongming Biotechnology Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20211111 Address after: 310000 Room 203, No. 2, Tianyuan Road, Fuchun street, Fuyang City, Hangzhou City, Zhejiang Province Applicant after: Li Haihua Address before: 310000 Room 102, building 30, Yinhu Science Park, No. 15, Fuxian Road, Yinhu street, Fuyang District, Hangzhou City, Zhejiang Province Applicant before: Zhejiang muzhongming Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |
|
| RJ01 | Rejection of invention patent application after publication |